Resonance Health logo

Resonance Health(ASX) RHT

Market CapA$38.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1994)-99%
5 Year-7%
1 Year+84%
1 Month+37%
A$0.08
+1.25%
+0.00Today
Resonance Health last closing stock price
MetricPriceDate
Last closeAUD 0.082026-10-09
Resonance Health stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+14.08%AUD 0.072026-10-02
1 month+37.29%AUD 0.062026-09-09
3 month+80%AUD 0.052026-07-09
Year to date+65.31%AUD 0.052025-12-31
1 year+84.09%AUD 0.042025-10-09
3 year+14.08%AUD 0.072023-10-10
5 year-6.9%AUD 0.092021-10-08
Since inception-99.42%AUD 14.091994-04-25

Resonance Health Financials at a Glance

Market Cap

A$38.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$26.82M

Net Income (TTM)

-A$219.64K

EPS (TTM)

A$0.00

P/E Ratio

25.31

Dividend

A$0.00

Beta (Volatility)

0.14 (Low)

Price

A$0.08

Volume

264,598

Open

A$0.08

Previous Close

A$0.08

Daily Range

A$0.08 - A$0.08

52-Week Range

A$0.04 - A$0.08

Estimated Earnings Date

Feb 26, 2026

RHT News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Resonance Health

Resonance Health Limited is a global provider of healthcare technology and services, specializing in software-as-medical devices. The company focuses on non-invasive, MRI-based diagnostic tools and serves diverse markets across the Asia Pacific, Americas, Europe, Middle East, and Africa.

Products and Services
  • FerriScan for quantifying liver iron concentration
  • HepaFat-AI for real-time liver fat quantification
  • Comprehensive biomarker services for clinical trials
Growth Outlook
  • Recent quarterly revenue reached AUD 7.78 million, showing strong demand
  • TTM gross profit margin stands at 93.9%, indicating operational efficiency
  • Expansion into new markets is anticipated to drive future growth
Financial Highlights
  • Net income for the latest quarter was AUD 47,060, reflecting profitability
  • Cash flow from operating activities was AUD 2.71 million, showcasing liquidity
  • Current ratio of 1.13 indicates solid short-term financial health
Resonance Health Limited has established itself as a leader in healthcare technology, particularly in the realm of MRI diagnostics. The company's innovative products, such as FerriScan and HepaFat-AI, are designed to enhance the accuracy of liver disease assessments, which is critical in managing patient care. The recent financial performance demonstrates a positive trajectory, with significant revenue growth and a strong gross profit margin, underscoring the company's operational efficiency. The growth outlook remains promising, with plans for market expansion and a focus on developing new technologies. The financial health of the company is supported by a solid current ratio and positive cash flow from operations, which provides a cushion for future investments and growth initiatives. Overall, Resonance Health Limited presents a compelling opportunity for investors interested in the healthcare technology sector.
AI Generated • Sep 22, 2026

Industry

Healthcare Equipment and Supplies

Employees

65

CEO

Andrew Duncan Harrison

Headquarters

Burswood, WA 6100, AU

RHT Financials

Key Financial Metrics (TTM)

Gross Margin

93.95%

Operating Margin

9.72%

Net Income Margin

9.61%

Return on Equity

13.72%

Return on Capital

10.26%

Return on Assets

8.07%

Earnings Yield

3.95%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$38.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

477.12M

Volume

264.60K

Avg. Volume

412.25K

Financials (TTM)

Gross Profit

A$25.87M

Operating Income

A$1.77M

EBITDA

A$1.87M

Operating Cash Flow

A$4.13M

Capital Expenditure

-A$537.89K

Free Cash Flow

A$3.59M

Cash & ST Invst.

A$4.85M

Total Debt

A$3.81M

Resonance Health Performance Analysis

Resonance Health annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 4,404,36015.1%
20242024-06-30AUD 8,589,49095.0%
20252025-06-30AUD 11,073,01828.9%
20262026-06-30AUD 15,751,90942.3%
Resonance Health sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-2.1%
Q42025-06-3012.5%
Q22025-12-3136.0%
Q42026-06-30-2.5%
Resonance Health annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.00-32.0%
20242024-06-30AUD 0.00N/A
20252025-06-30AUD -0.00N/A
20262026-06-30AUD 0.00N/A
Resonance Health sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-243.7%
Q42025-06-3034.8%
Q22025-12-31300.0%
Q42026-06-30-96.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$7.78M

+46.1%

Gross Profit

A$7.30M

+37.1%

Gross Margin

93.89%

N/A

Market Cap

A$38.65MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.15M

N/A

Employees

18

N/A

Net Income

A$47.06K

-93.5%

EBITDA

A$900.05K

+265.1%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$4.85M

-29.3%

Total Debt

A$3.81M

+3.1%

Accounts Receivable

A$2.47M

+6.6%

Inventory

A$0.00

N/A

Long Term Debt

A$1.05M

-67.4%

Short Term Debt

A$2.77M

+462.4%

Return on Assets

8.07%

N/A

Return on Invested Capital

12.59%

N/A

Free Cash Flow

A$2.65M

+75.3%

Operating Cash Flow

A$2.71M

+76.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HMD.AXHeraMED Limited
A$0.04-7.14%
IME.AXImExHS Limited
A$0.30+0.00%
AT1.AXAtomo Diagnostics Limited
A$0.02+0.00%
IDT.AXIDT Australia Limited
A$0.04+2.70%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About RHT

What is the current price of Resonance Health?

Resonance Health is trading at A$0.08 per share.

What is the 52-week range for Resonance Health?

Over the past 52 weeks, Resonance Health has traded between A$0.04 and A$0.08.

How much debt does Resonance Health have?

As of the most recent reporting period, Resonance Health reported total debt of A$3.81M.

How much cash does Resonance Health have on hand?

Resonance Health reported A$4.85M in cash and cash equivalents in its most recent financial results.

What is Resonance Health’s dividend yield?

Resonance Health does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.